158 related articles for article (PubMed ID: 33025406)
1. Can random bladder biopsies be eliminated after bacillus Calmette-Guérin therapy against carcinoma in situ?
Takamatsu K; Matsumoto K; Kikuchi E; Ogihara K; Hayakawa N; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Asanuma H; Mikami S; Oyama M; Oya M
Int Urol Nephrol; 2021 Mar; 53(3):465-469. PubMed ID: 33025406
[TBL] [Abstract][Full Text] [Related]
2. Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can post-induction random bladder biopsies be avoided?
Smith PJ; Lotan Y; Raj GV; Sagalowsky AI; Margulis V
Cytopathology; 2014 Apr; 25(2):108-11. PubMed ID: 23551700
[TBL] [Abstract][Full Text] [Related]
3. Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary?
Calò B; Sanguedolce F; Falagario UG; Chirico M; Fortunato F; Carvalho-Diaz E; Busetto GM; Bettocchi C; Carrieri G; Cormio L
World J Urol; 2021 Oct; 39(10):3815-3821. PubMed ID: 33830306
[TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
[TBL] [Abstract][Full Text] [Related]
5. Routine bladder biopsy after bacille Calmette-Guérin treatment: is it necessary?
Skemp NM; Fernandes ET
Urology; 2002 Feb; 59(2):224-6. PubMed ID: 11834390
[TBL] [Abstract][Full Text] [Related]
6. Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guérin (BCG) treatment.
Nurminen P; Ettala O; Seppänen M; Taimen P; Boström PJ; Kaipia A
BJU Int; 2019 Feb; 123(2):246-251. PubMed ID: 29959824
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
Narayan VM; Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE; Poch M; Crispen PL; Steinberg GD; Schuckman AK; Downs TM; Mashni J; Lane BR; Guzzo TJ; Bratslavsky G; Karsh LI; Woods ME; Brown G; Canter D; Luchey A; Lotan Y; Inman BA; Williams MB; Cookson MS; Chang SS; Sankin AI; O'Donnell MA; Sawutz D; Philipson R; Parker NR; Yla-Herttuala S; Rehm D; Jakobsen JS; Juul K; Dinney CPN
J Urol; 2024 Jul; 212(1):74-86. PubMed ID: 38704840
[TBL] [Abstract][Full Text] [Related]
8. The value of transurethral bladder biopsy after intravesical bacillus Calmette-Guérin instillation therapy for nonmuscle invasive bladder cancer: a retrospective, single center study and cumulative analysis of the literature.
Swietek N; Waldert M; Rom M; Schatzl G; Wiener HG; Susani M; Klatte T
J Urol; 2012 Sep; 188(3):748-53. PubMed ID: 22819422
[TBL] [Abstract][Full Text] [Related]
9. Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy?
Dalbagni G; Rechtschaffen T; Herr HW
J Urol; 1999 Sep; 162(3 Pt 1):708-9. PubMed ID: 10458348
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
Li R; Sexton WJ; Dhillon J; Berglund A; Naidu S; Borjas G; Rose K; Kim Y; Wang X; Conejo-Garcia JR; Jain RK; Poch MA; Spiess PE; Pow-Sang J; Gilbert SM; Zhang J
Clin Cancer Res; 2023 Oct; 29(19):3875-3881. PubMed ID: 37505486
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy.
Savic S; Zlobec I; Thalmann GN; Engeler D; Schmauss M; Lehmann K; Mattarelli G; Eichenberger T; Dalquen P; Spieler P; Schoenegg R; Gasser TC; Sulser T; Forster T; Zellweger T; Casella R; Bubendorf L
Int J Cancer; 2009 Jun; 124(12):2899-904. PubMed ID: 19230026
[TBL] [Abstract][Full Text] [Related]
12. Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guérin immunotherapy.
Kim SJ; You D; Jeong IG; Song C; Hong B; Kim CS; Ahn H; Hong JH
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2131-2140. PubMed ID: 31227894
[TBL] [Abstract][Full Text] [Related]
13. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
Haase RN; Harving N
Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
[No Abstract] [Full Text] [Related]
14. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
16. Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette-Guérin immunotherapy.
Subiela JD; Rodríguez Faba Ó; Aumatell J; Calderón J; Mercadé A; Balañà J; Esquinas C; Algaba F; Breda A; Palou J
BJU Int; 2022 Apr; 129(4):542-550. PubMed ID: 34375494
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Guérin.
Andius P; Damm O; Holmäng S
Scand J Urol Nephrol; 2004; 38(4):285-90. PubMed ID: 15669587
[TBL] [Abstract][Full Text] [Related]
18. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
19. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H
Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
[TBL] [Abstract][Full Text] [Related]
20. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
